Board summary
Key figures
38,724
Registered population
57.4% aged 18–64
26.6%
Aged 65+
ICB 20.0% · England 17.9%
2.5%
Ethnic minority (non-White)
0.8% Asian
0.0%
In IMD quintile 1
ICB 30.6% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
6,553
Hypertension register
+6.37% in 3 yrs · England +5.60%
358
SMI register
16.2% of Westmorland and Furness (LAD)'s
708
COPD register
Reviews -11.00% in 3 yrs
Forecast to 2030
7,525
Hypertension patients, 2030
+972 on today
74.7%
QRISK ≥20% on statins, 2030
+5.27pp over 3 yrs
6.1%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
COPD annual review coverage fell over three years.
COPD annual review coverage fell 11.0% over three years (England +2.8%) to 75.0% (England 76.4%), which may reflect follow-up capacity constraints.
Age-five MMR coverage drops between doses.
In Q1 2025/26, age-5 MMR coverage drops 9 pp from 98.9% (dose 1) to 89.9% (dose 2), below the 95.0% target.
Non-frail diabetes HbA1c control outpaced England growth.
Non-frail diabetes HbA1c control rose +12.3% over three years (England +4.4%, ICB +7.9%), reaching 57.5% against 57.4% across England.
Population, age and ethnicity
Patients aged 65+ make up 26.6% of the list, 8.7 percentage points above England
Kendal PCN cares for 38,724 registered patients across three practices. Patients aged 65+ comprise 26.6% (10,315 patients), above Westmorland and Furness (25.9%), the ICB (20.0%) and England (17.9%). Those aged 18–64 account for 57.4% (LAD 58.4%, ICB 60.4%, England 62.7%) and aged 0–17 represent 16.0% (LAD 15.8%, ICB 19.6%, England 19.6%). Census resident estimates show 97.5% White ethnicity and a 2.5% ethnic minority share, reflecting residential areas rather than GP lists. List growth is projected at 1.1% to 2030 (LAD 1.7%, ICB 1.7%, England 2.3%), using unverified methodology.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Westmorland and Furness (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Westmorland and Furness LA) | 1,591 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.5% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.5% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Westmorland and Furness LA) | 736 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Westmorland and Furness LA) | 10.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Kendal PCN records an average IMD decile of 7.4 and 0.0% in Core20
The PCN has an average IMD decile of 7.4 (Captain French Surgery and The James Cochrane Pract. at 7.4, Station House Surgery at 7.5), less deprived than Westmorland and Furness (6.0), the ICB (5.0), and England (5.5). Registered Core20 patients stand at 0.0% (0 patients), below Westmorland and Furness (9.2%), the ICB (30.6%), and England (21.0%). Across all three practices, Core20 share reconciles at 0.0% (0 patients).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
358
SMI register
0.92% recorded prevalence
263
Learning disability register
0.68% recorded prevalence
16
Care homes, 505 beds
In the PCN catchment
The PCN records 263 learning disability patients (0.7% prevalence vs Westmorland and Furness 0.6%, the ICB 0.6% and England 0.6%) and 358 severe mental illness patients (0.9% vs Westmorland and Furness 0.9%, the ICB 1.2% and England 1.0%). Catchment facilities include 16 care homes with 505 beds, though PCN resident share is unconfirmed. Recorded learning disability prevalence exceeds England, though crude register rates do not establish unmet need.
Severe mental illness: physical health checks
For 358 SMI patients, BMI recording is 73.3% (England 82.1%), reaching 65.9% at Captain French Surgery and 65.9% at Station House Surgery. Blood pressure checks reach 79.8% (England 83.4%), and alcohol recording in psychosis is 68.5% (England 81.8%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,553
Hypertension register
+6.37%
Register growth, 3 yrs
Westmorland and Furness (LAD) +6.93% · England +5.60%
+0.35pp
BP control, under 80
≤140/90 · +1.69pp aged 80+
+972
More patients by 2030
Forecast 7,525 (19.07%)
Hypertension case-finding and control
Hypertension recorded prevalence is 16.9% (6,553 patients), above England (15.2%) but below Westmorland and Furness (18.2%). Recent blood pressure recording reached 92.3%, exceeding England (90.0%) and the ICB (89.0%). Blood pressure control under age 80 is 64.2%, trailing England (67.8%) and Westmorland and Furness (68.0%). Across practices, control under age 80 is 60.6% at Station House Surgery, 64.2% at The James Cochrane Pract., and 68.3% at Captain French Surgery.
Lipids and statins
Statin treatment in diabetes reaches 69.7% without cardiovascular disease (England 73.2%) and 81.5% with cardiovascular disease (England 84.4%). For QRISK at or above 20%, lipid-lowering therapy is 62.7% (England 63.6%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 93,841 | £1.40 | £1.64 | £1.86 | £131,377 |
| Cardiovascular (all), 2025 | 113,846 | £2.82 | £3.38 | £3.33 | £321,046 |
For lipid-regulating drugs in 2026, Kendal PCN prescribed 93,841 items at £1.40 per item, below England (£1.86) and the ICB (£1.64). Across these items, the PCN spent £43,167 less than at England's unit cost and £22,522 less than at the ICB's unit cost. Unit-cost differences do not indicate prescribing efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+3.70%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.79%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 1.8% (708 patients), with three-year change of +6.0% (England +2.6%), while annual reviews fell 11.0% (England +2.8%) to 75.0% (England 76.4%, Westmorland and Furness 79.2%). For 2,706 asthma patients (7.3% prevalence), review coverage is 64.8% (Westmorland and Furness 70.4%), leaving about 950 patients unreviewed. Second-hand smoke recording for asthma patients aged 6-19 is 64.9% (England 78.8%), alongside 1,736 asthma management items prescribed per 1,000 patients aged 5-19.
Cancer register and children's immunisation
The cancer register records 1,908 patients (4.9% prevalence, England 3.8%). In Q1 2025/26, MMR first-dose coverage at age 5 was 98.9% (cohort of 89), but second-dose coverage fell 9 pp to 89.9% (England 82.8%), 5.1 pp below the 95.0% target. At practice level, the drop was 10.7 pp at Captain French Surgery and 12.5 pp at Station House Surgery. Complete 6-in-1 coverage at 24 months was 92.6%.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, 52.4% of cancers with a known stage in NHS Lancashire and South Cumbria ICB were diagnosed at stage 1 or 2 (4,642 of 8,863 staged cases), trailing England (55.3%) by 2.9 percentage points and sitting 22.6 pp below the 75.0% national ambition by 2028. Known-stage coverage was 74.6% (8,863 of 11,883 registrations). Reaching 75.0% would require about 2,010 additional early-stage diagnoses annually across the ICB. Bowel (44.2%) and lung (31.1%) show substantial early-stage deficits. These ICB figures reflect system context, not Kendal PCN performance, and exclude unstageable tumours. Lower ICB early detection may elevate late-stage risks, which is consistent with prioritising robust practice-level safety-netting.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, University Hospitals of Morecambe Bay NHS Foundation Trust reached 72.4% on the 62-day cancer treatment standard, 12.6 pp below the 85.0% standard. This was ahead of North Cumbria Integrated Care NHS Foundation Trust (70.9%), Blackpool Teaching Hospitals NHS Foundation Trust (67.5%) and England (71.2%), but below NHS Lancashire and South Cumbria Integrated Care Board (73.6%). The trust met the 28-day faster diagnosis standard at 78.4% (standard 75.0%). In diagnostics, 10.4% waited 6+ weeks across all tests (England 23.1%), though CT was 13.8% (England 9.9%). Longer treatment waits could reflect downstream therapeutic bottlenecks rather than diagnostic delays.
| Pathways within standard (%) | of Morecambe Bay | North Cumbria Integrated Care | Blackpool | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.39 | 78.33 | 71.38 | 78.39 | 79.32 |
| 31-day treatment (96%) | 95.22 | 93.09 | 97.96 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 72.35 | 70.90 | 67.48 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | of Morecambe Bay | North Cumbria Integrated Care | Blackpool | England |
|---|---|---|---|---|
| MRI | 4.04 | 9.59 | 21.80 | 21.40 |
| CT | 13.76 | 0.63 | 16.49 | 9.92 |
| Echocardiography | 10.55 | 1.33 | 7.57 | 28.48 |
| Colonoscopy | 0.60 | 5.50 | 13.08 | 30.83 |
| Gastroscopy | 1.45 | 10.90 | 12.47 | 29.02 |
| All 15 DM01 tests | 10.44 | 16.60 | 26.54 | 23.14 |
| Community services activity | Westmorland and Furness residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 53,485 | 193,720 |
| Referrals | 6,470 | 29,855 |
| Patients with a contact | 13,445 | 65,335 |
Community services (residents of Westmorland and Furness), Jun 2026 (provisional). In June 2026, Westmorland and Furness residents accounted for 249,980 provisional community care activities, within 533,345 recorded across NHS Lancashire and South Cumbria Integrated Care Board. Adults aged 65+ represented 67.9% of borough resident contacts (36,330 of 53,485). These experimental figures reflect broad resident activity rather than PCN-specific delivery, which is consistent with heavy reliance on out-of-hospital community services to support the area's older population.
Practice variation and patient experience
Patient experience spans 19.7 pp across practices alongside a 28.6 pp vaccination variation
Across practices, 2025/26 QOF overall achievement is 93.1% at Captain French Surgery, 96.4% at Station House Surgery, and 97.3% at The James Cochrane Pract. Clinical achievement is at least 98.0% across all three, but vaccination and immunisation achievement spans 28.6 pp, from 54.9% at Captain French Surgery to 83.5% at The James Cochrane Pract.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Captain French | 121 | 0.0 | 84.0% | 65.6% | 95.2% |
| Station House | 113 | 0.0 | 87.0% | 70.5% | 88.2% |
| James Cochrane | 95 | 0.0 | 70.5% | 81.8% | 75.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fourteen tracked measures trail England over three years despite strong diabetes control gains
Over 2023 to 2025, 14 of 25 tracked measures trailed England's trajectory. Annual reviews fell 11.0% for COPD (England +2.8%) and 4.9% for heart failure (England +8.7%). Psychosis alcohol recording fell 2.1 pp (England +5.4 pp) and learning disability prevalence fell 1.7% (England +5.4%). Conversely, non-frail diabetes HbA1c control rose +12.3% (England +4.4%) to 57.5%, hypertension blood pressure recording rose +6.5% (England +3.6%) to 92.3%, and statins in diabetes without CVD rose +5.7% (England +2.1%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
Heart failure reviews
Alcohol record (psychosis)
Learning disability register
BMI record (SMI)
Diabetes HbA1c control
Diabetes statin (no CVD)
Hypertension BP reading
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Westmorland and Furness (LAD) | Asset | PCN | Westmorland and Furness (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 16 (505 beds) | n/a | Schools (catchment) | 43 | n/a |
| Children's centres | 2 | 12 | Places of worship | 36 | 316 |
| Libraries | n/a | 14 | Food banks (VCS) | 1 | 2 |
| Day centres (VCS) | 1 | 2 | Children and young people (VCS) | n/a | 3 |
| Carers support groups (VCS) | n/a | 2 | Primary schools (LA maintained) | 13 | 82 |
| Primary academies | 4 | 27 | Special schools | 2 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma annual review and smoke recall
Asthma review coverage is 64.8% of 2,706 patients (Westmorland and Furness 70.4%, England 65.7%), leaving 953 unreviewed; ages 6-19 second-hand smoke recording is 64.9% (England 78.8%). Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Age-five MMR2 pre-school booster recall
In Q1 2025/26 (cohort 89), age-5 MMR coverage drops 9 pp from 98.9% (MMR1) to 89.9% (MMR2), with drops of 12.5 pp at Station House Surgery and 10.7 pp at Captain French Surgery. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
COPD annual review and register audit
COPD prevalence is 1.8% (708 patients) vs England (1.9%) and Westmorland and Furness (2.0%), a modelled gap of +26 to +72; annual reviews fell 11.0% over 2023 to 2025 to 75.0% (borough 79.2%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult proactive care review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Target inclusion health and PLUS groups (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension treatment titration audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Suspected cancer safety-netting review (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Telephony and access triage review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Asthma annual review and smoke recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Age-five MMR2 pre-school booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · COPD annual review and register audit (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
